

# Osteoarthritis Injectables Market Booming: Set for US\$ 16.2 Bn by 2034; Anticipated to Gain CAGR of 6.9%(2024 – 2034);TNR

*Global Osteoarthritis Injectables Market is Advancing Due to Rising OA Prevalence in Aging Populations & Increased R&D in Injectable Drug Development*

WILMINGTON, DELAWARE, UNITED STATES, June 19, 2024

[/EINPresswire.com/](https://www.einpresswire.com/) -- Osteoarthritis

injectables refer to therapeutic

substances administered directly into

joints affected by osteoarthritis to

alleviate pain, reduce inflammation, and improve joint function. These injectables commonly include hyaluronic acid, corticosteroids, and platelet-rich plasma (PRP). Hyaluronic acid acts as a lubricant and shock absorber within the joint, enhancing mobility and reducing discomfort. Corticosteroids, potent anti-inflammatory agents, provide rapid relief by reducing inflammation and swelling in the joint. PRP, derived from the patient's own blood, contains growth factors that promote tissue repair and regeneration, aiming to improve joint health over time. These treatments offer targeted relief without the systemic side effects associated with oral medications and are particularly beneficial for patients seeking non-surgical alternatives or those who have not responded adequately to conventional therapies. Osteoarthritis injectables play a crucial role in managing symptoms and improving quality of life for individuals affected by this degenerative joint disease.

[Visit our Homepage](#)

Osteoarthritis injectables present significant opportunities in the healthcare landscape by offering minimally invasive treatment options for managing joint pain and improving mobility. The growing aging population and increasing prevalence of osteoarthritis globally provide a substantial market opportunity for these therapies. They cater to patients seeking effective pain relief and functional improvement without the risks and recovery associated with surgery. Challenges include the variability in patient response to treatments like corticosteroids and hyaluronic acid, which may require personalized approaches. Additionally, navigating regulatory approvals and ensuring widespread access to advanced injectables in healthcare systems

The logo for TNR THE NICHE RESEARCH. The letters "TNR" are large, bold, and orange. Below them, the words "THE NICHE RESEARCH" are written in a smaller, grey, sans-serif font.

present logistical hurdles. Moreover, while injectables offer localized treatment benefits, they require skilled administration and monitoring to optimize outcomes. Addressing these challenges through ongoing research, technological advancements, and healthcare infrastructure improvements will be crucial in maximizing the potential of osteoarthritis injectables in meeting the diverse needs of patients worldwide.

## Global Osteoarthritis Injectables Market: Key Inclusions

Corticosteroid Injections segment is projected to be fastest growing segment in the osteoarthritis injectables market over the forecast period (2024-2034). Corticosteroid injections are a pivotal component of osteoarthritis injectables, primarily driven by their ability to provide rapid and effective pain relief. These injections contain powerful anti-inflammatory agents that directly target joint inflammation, a hallmark of osteoarthritis. As the global population ages and obesity rates rise, there is an increasing prevalence of osteoarthritis, particularly in weight-bearing joints like the knees and hips, which amplifies the demand for corticosteroid treatments. Unlike oral medications, corticosteroid injections deliver medication directly into the affected joint, offering quicker onset of pain relief and reducing systemic side effects. The preference for minimally invasive treatments among patients and healthcare providers further fuels demand for corticosteroid injections, as they allow for improved joint function and mobility without the need for invasive surgery. Advances in injection techniques and formulations continue to enhance their efficacy and safety profile, solidifying their position as a cornerstone in the management of osteoarthritis worldwide.

### [Get Sample Copy of the Report](#)

Hip osteoarthritis segment in the osteoarthritis injectables market is expected to gain momentum over the years to come. The demand for osteoarthritis injectables for hip osteoarthritis is driven by several key factors specific to this joint and its functional importance. Hip osteoarthritis is prevalent among aging populations, where wear and tear on the joint over time leads to pain, stiffness, and reduced mobility. Injectables such as corticosteroids, hyaluronic acid, and platelet-rich plasma (PRP) offer targeted relief by reducing inflammation, lubricating the joint, and promoting healing processes, respectively. The aging demographic, particularly in developed regions, underscores the need for effective pain management solutions that can delay or alleviate the need for surgical interventions like hip replacements. Moreover, the trend towards minimally invasive treatments aligns with patient preferences for therapies that provide rapid relief without the prolonged recovery times associated with surgery. As awareness grows and medical technology advances, the market for hip osteoarthritis injectables continues to expand, driven by the desire to maintain mobility and improve quality of life among affected individuals.

Asia-Pacific region is expected to experience the highest growth rate in the osteoarthritis injectables market. The demand for osteoarthritis injectables in the Asia Pacific region is driven by a combination of demographic and lifestyle factors. The region's rapidly aging population,

particularly in countries like Japan and China, significantly increases the prevalence of osteoarthritis, necessitating effective treatment options. Additionally, rising obesity rates and sedentary lifestyles contribute to the higher incidence of osteoarthritis, further boosting demand for injectable treatments. Advances in medical technology and increased healthcare expenditure have improved access to these minimally invasive therapies. Growing patient awareness and acceptance of injectables, coupled with a cultural shift towards maintaining an active lifestyle despite aging, also play crucial roles. Furthermore, government initiatives to enhance healthcare infrastructure and services in emerging economies are facilitating greater adoption of advanced treatments, including osteoarthritis injectables. These combined factors are driving the robust growth of the osteoarthritis injectables market in the Asia Pacific, addressing the region's growing need for effective osteoarthritis management solutions.

#### Global Osteoarthritis Injectables Market Key Players:

- Anika Therapeutics, Inc.
- Arthrex, Inc.
- Bioventus.
- Ferring Pharmaceuticals Inc.
- Flexion Therapeutics, Inc.
- Royal Biologics
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- Zimmer Biomet
- Other Industry Participants

#### [Browse Related Category Reports](#)

#### Global Osteoarthritis Injectables Market

##### Global Osteoarthritis Injectables Market Injection Type Outlook (Revenue, USD Million, 2016 - 2034)

- Hyaluronic Acid Injections
- Corticosteroid Injections
- Platelet-rich Plasma (PRP) Injections
- Placental Tissue Matrix (PTM) Injections
- Acetylsalicylic Acid (ASA) Injections
- Others

##### Global Osteoarthritis Injectables Market Anatomy Outlook (Revenue, USD Million, 2016 - 2034)

- Knee Osteoarthritis
- Hip Osteoarthritis
- Hand Osteoarthritis
- Others

## Global Osteoarthritis Injectables Market End User Outlook (Revenue, USD Million, 2016 - 2034)

- Hospital Pharmacies
- Retail Pharmacies
- Others

## Global Osteoarthritis Injectables Market Regional Outlook (Revenue, USD Million, 2016 - 2034)

- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)

Jay Reynolds

The Niche Research

+1 302-232-5106

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/721210307>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.